Company: NKLR
Filing Date: 2025-12-16
Form Type: 424B3
Source: 0001213900-25-121900
Chunk: 195

Company: Terra Innovatum Global N.V.
Filing Date: 2025-12-16
Form: 424B3
Chunk 195
---
 (the “Business Combination Agreement”) with Terra Innovatum s.r.l., an Italian limited liability company (“Terra
Innovatum”). Pursuant to the terms of the Business Combination Agreement, on October 9, 2025, the Company, Terra Innovatum and
their related parties undertook a series of reorganizations, equity issuances, and purchases, resulting in the Company becoming a wholly
owned subsidiary of a Dutch public limited liability company (“Pubco”), which was formed as part of the transaction (the
“Business Combination”), as further described in Note 10.

Financing

The registration statement for the Company’s Initial Public
Offering was declared effective on November 7, 2024. On November 8, 2024, the Company consummated the Initial Public Offering of 23,000,000
units including 3,000,000 additional public units as the underwriters’ over-allotment option was exercised in full (the “Units”
and, with respect to the shares of Class A ordinary shares included in the Units being offered, the “Public Shares”), at
$10.00 per Unit, generating gross proceeds of $230,000,000 (see Note 3).

Simultaneously with the consummation of the Initial Public Offering
and the sale of the Units, the Company consummated the private placement (“Private Placement”) of 422,500 units including
7,500 additional private placement units as the underwriters’ over-allotment option was exercised in full (the “Private Placement
Units”) to GSR III Sponsor LLC (the “Sponsor”), at a price of $10.00 per Private Placement Unit, generating total proceeds
of $4,225,000, which is described in Note 4. This amount from the sale of the Private Placement Units are added to the net proceeds from
the Initial Public Offering held in the Trust Account. The proceeds received from the sale of the Private Placement Units held in the
Trust Account was used partially to pay some general and administrative expenses.

Transaction costs amounted to $11,084,352, consisting of $975,000
of cash underwriting fees, $9,200,000 of deferred underwriting fees which will be paid on the consummation of initial Business Combination,
and $909,352 of other offering costs.

<div align='center'>F-7</div>

Upon the closing of the Initial Public Offering and the Private Placement,
$230,000,000 ($10